Added value of 18F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study
Authors: Ceccaldi Mathieu , Jonveaux Thérèse , Verger Antoine , Krolak‐Salmon Pierre , Houzard Claire , Godefroy Olivier , Shields Trevor , Perrotin Audrey , Gismondi Rossella , Bullich Santiago , Jovalekic Aleksandar , Raffa Nicola , Pasquier Florence , Semah Franck , Dubois Bruno , Habert Marie‐Odile , Wallon David , Chastan Mathieu , Payoux Pierre ,   NEUUS in AD study group, Ceccaldi Mathieu , Guedj Eric , Ceccaldi Mathieu , Felician Olivier , Didic Mira , Gueriot Claude , Koric Lejla , Kletchkova‐Gantchev Radka , Guedj Eric , Godefroy Olivier , Andriuta Daniela , Devendeville Agnès , Dupuis Diane , Binot Ingrid , Barbay Mélanie , Meyer Marc‐Etienne , Moullard Véronique , Magnin Eloi , Chamard Ludivine , Haffen Sophie , Morel Olivier , Drouet Clément , Boulahdour Hatem , Goas Philippe , Querellou‐Lefranc Solène , de la Sayette Vincent , Cogez Julien , Branger Pierre , Agostini Denis , Manrique Alain , Rouaud Olivier , Bejot Yannick , Jacquin‐Piques Agnès , Dygai‐Cochet Inna , Berriolo‐Riedinger Alina , Moreaud Olivier , Sauvee Mathilde , Crépin Céline Gallazzani , Pasquier Florence , Bombois Stéphanie , Lebouvier Thibaud , Mackowiak‐Cordoliani Marie‐Anne , Deramecourt Vincent , Rollin‐Sillaire Adeline , Cassagnaud‐Thuillet Pascaline , Chen Yaohua , Semah Franck , Petyt Grégory , Krolak‐Salmon Pierre , Federico Denis , Danaila Keren Liora , Guilhermet Yves , Magnier Christophe , Makaroff Zaza , Rouch Isabelle , Xie Jing , Roubaud Caroline , Coste Marie‐Hélène , David Kenny , Sarciron Alain , Waissi Aziza Sediq , Scheiber Christian , Houzard Claire , Gabelle‐Deloustal Audrey , Bennys Karim , Marelli Cecilia , Touati Lynda , Mariano‐Goulart Denis , de Verbizier‐Lonjon Delphine , Jonveaux Thérèse , Benetos Athanase , Kearney‐Schwartz Anna , Perret‐Guillaume Christine , Verger Antoine , Vercelletto Martine , Boutoleau‐Bretonniere Claire , Pouclet‐Courtemanche Hélène , Wagemann Nathalie , Pallardy Amandine , Hugon Jacques , Paquet Claire , Dumurgier Julien , Millet Pascal , Queneau Mathieu , Dubois Bruno , Epelbaum Stéphane , Levy Marcel , Habert Marie‐Odile , Novella Jean‐Luc , Jaidi Yacine , Papathanassiou Dimitri , Morland David , Belliard Serge , Salmon Anne , Lejeune Florence , Hannequin Didier , Wallon David , Martinaud Olivier , Zarea Aline , Chastan Mathieu , Pariente Jérémie , Thalamas Claire , Galitzky‐Gerber Monique , Tricoire Ricard Anne‐Marie , Calvas Fabienne , Rigal Emilie , Payoux Pierre , Hitzel Anne , Delrieu Julien , Ousset Pierre‐Jean , Lala Françoise , Sastre‐Hengan Nathalie , Stephens Andrew , Guedj Eric 
Published: November 2017

Introduction

Although some studies have previously addressed the clinical impact of amyloid positron emission tomography (PET), none has specifically addressed its selective and hierarchical implementation in relation to cerebrospinal fluid analysis in a naturalistic setting.

Methods

This multicenter study was performed at French tertiary memory clinics in patients presenting with most complex clinical situations (i.e., early‐onset, atypical clinical profiles, suspected mixed etiological conditions, unexpected rate of progression), for whom cerebrospinal fluid analysis was indicated but either not feasible or considered as noncontributory (ClinicalTrials.gov: NCT02681172).

Results

Two hundred five patients were enrolled with evaluable florbetaben PET scans; 64.4% of scans were amyloid positive. PET results led to changed diagnosis and improved confidence in 66.8% and 81.5% of patients, respectively, and altered management in 80.0% of cases.

Discussion

High‐level improvement of diagnostic certainty and management is provided by selective and hierarchical implementation of florbetaben PET into current standard practices for the most complex dementia cases.